<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<HR SIZE="2" STYLE="color: Black">

<HR SIZE="1" STYLE="color: Black">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WASHINGTON, DC 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CURRENT REPORT PURSUANT TO SECTION 13 OR
15(D) OF</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">THE SECURITIES EXCHANGE ACT OF 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt">Date of report (Date of earliest event reported)</TD>
    <TD STYLE="width: 50%; border-bottom: black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: right">June 26, 2012</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: black 1.5pt solid; font-size: 18pt; font-weight: bold; text-align: center">NANOVIRICIDES, INC.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center">(Exact Name of Registrant as Specified in Its Charter)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="width: 33%; vertical-align: top; font-weight: bold; text-align: center">Nevada</TD>
    <TD STYLE="width: 34%; vertical-align: top; font-weight: bold; text-align: center">000-1379006</TD>
    <TD STYLE="width: 33%; vertical-align: bottom; font-weight: bold; text-align: center">76-0674577</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">(State or Other Jurisdiction of Incorporation)</TD>
    <TD STYLE="text-align: center">(Commission File Number)</TD>
    <TD STYLE="text-align: center">(I.R.S. Employer Identification No.)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>135 Wood Street, Suite 205</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>West Haven, Connecticut</B></P></TD>
    <TD STYLE="font-weight: bold; text-align: center">06516</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: center">(Address of Principal Executive Offices)</TD>
    <TD STYLE="text-align: center">(Zip Code)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; font-size: 10pt; font-weight: bold; text-align: center">(203) 937-6137</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center">(Registrant's Telephone Number, Including Area Code)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE ALIGN="CENTER" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-family: Wingdings">&uml;</TD>
    <TD>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Wingdings">&uml;</TD>
    <TD>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Wingdings">&uml;</TD>
    <TD>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Wingdings">&uml;</TD>
    <TD>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 1.01 Entry into a Material Definitive Agreement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> On June 26, 2012, NanoViricides, Inc., a Nevada corporation (the &ldquo;Company&rdquo;), entered into
a Securities Purchase Agreement (the &ldquo;Agreement&rdquo;) with Seaside 88, LP, a Florida limited partnership (&ldquo;Seaside&rdquo;),
relating to the offering and sale (the &ldquo;Offering&rdquo;) of up to 5,000 shares of the Company&rsquo;s Series C Convertible
Preferred Stock, par value $0.001 per share (the &ldquo;Series C Preferred Stock&rdquo;) at the purchase price of $1,000 per share
(the &ldquo;Purchase Price&rdquo;) for an aggregate Offering of $5,000,000. On June 28, 2012, Seaside
purchased an initial 2,500 shares of the Series C Preferred Stock for an aggregate purchase price of $2,500,000 (the &ldquo;Initial
Closing&rdquo;). Ten business days following the date all the shares of Series C Preferred Stock sold in the Initial Closing have
been converted, conditioned upon the Company&rsquo;s satisfaction of conditions precedent to closing set forth in the Agreement,
Seaside will purchase the remaining 2,500 shares of the Series C Preferred Stock for the purchase price of $2,500,000 (the &ldquo;Subsequent
Closing&rdquo;). At each of the Initial Closing and Subsequent Closing, and every 14th day thereafter, a number of shares of Series
C Preferred Stock shall be converted into shares of the Company&rsquo;s common stock, par value $0.001 per share (the &ldquo;Common
Stock&rdquo;). At each conversion, the number of shares of Series C Preferred Stock (calculated to four places to the right of
the decimal point) that will convert into Common Stock shall be equal to the product of fifteen percent (15%) of the total number
of shares of Common Stock traded during the preceding ten (10) trading days and the applicable conversion price divided by $1,000,
subject to the Share Limit (below). At each conversion date, the conversion price for the Common Stock will equal the lower of
(i) 85% of the Common Stock&rsquo;s volume weighted average trading price (the &ldquo;VWAP&rdquo;) during the 10-day trading period
immediately preceding the conversion date and (ii) 88% of the VWAP of the Common Stock on the trading day immediately prior to
the conversion date. The number of shares of Common Stock issued upon such conversion shall then be determined by multiplying the
number of shares of Series C Preferred Stock converted by $1,000 and dividing the product thereof by the conversion price for such
conversion date, subject to certain limitations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that the VWAP for the 20 trading
day period immediately prior to a conversion does not equal or exceed $0.20 (the &ldquo;Floor&rdquo;), as calculated with respect
to any subsequent conversion date, then such conversion will not occur and the shares not converted on that date will be added
to shares of Series C Preferred Stock to be converted on the following conversion date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, Seaside has the right to reduce
the number of shares of Series C Preferred Stock converted on any conversion date if the number of shares of Common Stock to be
received Seaside upon conversion is greater than twice the number of shares of Common Stock received by Seaside in connection with
the immediately preceding conversion (the &ldquo;Share Limit&rdquo;). In such event, Seaside may reduce the number of shares of
Series C Preferred Stock converted on such conversion date such that the number of shares of Common Stock to be received is an
amount equal to, as near as possible, the applicable Share Limit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Agreement contains representations
and warranties and covenants for each party, which must be true and have been performed at each closing. Additionally, the Company
has agreed to indemnify and hold harmless Seaside and its related parties against certain liabilities in connection with the issuance
and sale of the Series C Preferred Stock under the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the Initial Closing, Seaside converted
146.7916 shares of Series C Preferred Stock into 298,472 shares of Common Stock at the conversion price of $0.49181, and the Company
raised gross proceeds of $2,500,000 before estimated Offering expenses of approximately $200,000, which includes placement agent
and attorneys&rsquo; fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Offering is made pursuant to the Company&rsquo;s
shelf registration statement on Form S-3 (File No. 333-165221), which was declared effective by the Securities and Exchange Commission
on April 29, 2010. The Company, pursuant to Rule 424(b) under the Securities Act of 1933, has filed with the Securities and Exchange
Commission a prospectus supplement relating to the Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Offering, pursuant
to a Placement Agency Agreement dated March 3, 2010 by and between Midtown Partners &amp; Co., LLC (&ldquo;Midtown&rdquo;) and
the Company, as amended by an Underwriter Agent Agreement Amendment No. 1 dated March 28, 2011 (as amended, the &ldquo;Placement
Agency Agreement&rdquo;), the Company will pay Midtown a cash fee representing 6% of the gross purchase price paid by Seaside for
the Series C Preferred Stock.</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing is only a summary of the
material terms of the Agreement and the Placement Agency Agreement. The foregoing description of the Agreement is qualified in
its entirety by reference to the Agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated
herein by reference. The foregoing description of the Placement Agency Agreement is qualified in its entirety by reference to the
Placement Agency Agreement and the Underwriter Agent Agreement Amendment No. 1, which are incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Current Report on Form 8-K contains
forward-looking statements that involve risk and uncertainties, such as statements related to the anticipated subsequent closings
of the Offering. The risks and uncertainties involved include the Company&rsquo;s ability to satisfy certain conditions to closing
on a timely basis or at all, the substantial dilution to current stockholders as a result of the purchase price discount offered
to Seaside, and the market overhang of shares available for sale that may develop as a result of the subsequent resale by Seaside
of the shares it may acquire under the Agreement, as well as other risks detailed from time to time in the Company&rsquo;s periodic
filings with the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-weight: bold">Item 9.01</TD>
    <TD COLSPAN="3">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Financial Statements and Exhibits.</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">(d)</TD>
    <TD COLSPAN="3" STYLE="vertical-align: top; font-weight: bold">Exhibits.</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: top; font-weight: bold">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Number</B></P></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Description</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top">1.1</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">Placement Agency Agreement, dated March 3, 2010, by and between NanoViricides, Inc. and Midtown Partners &amp; Co., LLC.(1)</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top">1.2</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">Underwriter Agent Agreement Amendment No. 1 dated March 28, 2011(2)</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top">4.1</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">Certificate of Designation of Rights and Preferences of Series C Convertible Preferred Stock</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top">10.1</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">Securities Purchase Agreement dated June 26, 2012 by and between NanoViricides, Inc. and Seaside 88, LP.</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top">99.1</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">Press Release dated June 29, 2012</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="width: 29px">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(1) Incorporated by reference from the Company&rsquo;s
Form 8-K filed on May 12, 2010.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(2) Incorporated by reference from the Company&rsquo;s
Form 8-K filed on April 19, 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>PURSUANT TO THE REQUIREMENTS OF THE SECURITIES EXCHANGE ACT
OF 1934, THE REGISTRANT HAS DULY CAUSED THIS REPORT TO BE SIGNED ON ITS BEHALF BY THE UNDERSIGNED THEREUNTO DULY AUTHORIZED.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top">NANOVIRICIDES, INC.</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="width: 50%; vertical-align: top">&nbsp;</TD>
    <TD STYLE="width: 4%; vertical-align: top">&nbsp;</TD>
    <TD STYLE="width: 36%; vertical-align: top">&nbsp;</TD>
    <TD STYLE="width: 10%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">Date: June 29, 2012</TD>
    <TD STYLE="vertical-align: top">By:</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: top">&nbsp;/s/ Anil Diwan</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">Anil Diwan, President</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit Index</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: top; font-weight: bold">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Number</B></P></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Description</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top">1.1</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">Placement Agency Agreement, dated March 3, 2010, by and between NanoViricides, Inc. and Midtown Partners &amp; Co., LLC.(1)</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top">1.2</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">Underwriter Agent Agreement Amendment No. 1 dated March 28, 2011(2)</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top">4.1</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">Certificate of Designation of Rights and Preferences of Series C Convertible Preferred Stock</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top">10.1</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">Securities Purchase Agreement dated June 26, 2012 by and between NanoViricides, Inc. and Seaside 88, LP.</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top">99.1</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">Press Release dated June 29, 2012</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="width: 29px">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(1) Incorporated by reference from the Company&rsquo;s
Form 8-K filed on May 12, 2010.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(2) Incorporated by reference from the Company&rsquo;s
Form 8-K filed on April 19, 2011.</P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "v317343_8k.htm", "description": "8-K CURRENT REPORT", "secsgml_size_bytes": 25750}]
{"company-data": {"conformed-name": "NANOVIRICIDES, INC.", "cik": "0001379006", "assigned-sic": "8731", "irs-number": "760674577", "state-of-incorporation": "NV", "fiscal-year-end": "0630"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-52318", "film-number": "12936914"}, "business-address": {"street1": "135 WOOD STREET", "street2": "SUITE 205", "city": "WEST HAVEN", "state": "CT", "zip": "06516", "phone": "(203) 937-6137"}, "mail-address": {"street1": "135 WOOD STREET", "street2": "SUITE 205", "city": "WEST HAVEN", "state": "CT", "zip": "06516"}}
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR
15(D) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported)
June 26, 2012
NANOVIRICIDES, INC.
(Exact Name of Registrant as Specified in Its Charter)
Nevada
000-1379006
76-0674577
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
135 Wood Street, Suite 205
West Haven, Connecticut
06516
(Address of Principal Executive Offices)
(Zip Code)
(203) 937-6137
(Registrant's Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01 Entry into a Material Definitive Agreement.
On June 26, 2012, NanoViricides, Inc., a Nevada corporation (the "Company"), entered into
a Securities Purchase Agreement (the "Agreement") with Seaside 88, LP, a Florida limited partnership ("Seaside"),
relating to the offering and sale (the "Offering") of up to 5,000 shares of the Company's Series C Convertible
Preferred Stock, par value $0.001 per share (the "Series C Preferred Stock") at the purchase price of $1,000 per share
(the "Purchase Price") for an aggregate Offering of $5,000,000. On June 28, 2012, Seaside
purchased an initial 2,500 shares of the Series C Preferred Stock for an aggregate purchase price of $2,500,000 (the "Initial
Closing"). Ten business days following the date all the shares of Series C Preferred Stock sold in the Initial Closing have
been converted, conditioned upon the Company's satisfaction of conditions precedent to closing set forth in the Agreement,
Seaside will purchase the remaining 2,500 shares of the Series C Preferred Stock for the purchase price of $2,500,000 (the "Subsequent
Closing"). At each of the Initial Closing and Subsequent Closing, and every 14th day thereafter, a number of shares of Series
C Preferred Stock shall be converted into shares of the Company's common stock, par value $0.001 per share (the "Common
Stock"). At each conversion, the number of shares of Series C Preferred Stock (calculated to four places to the right of
the decimal point) that will convert into Common Stock shall be equal to the product of fifteen percent (15%) of the total number
of shares of Common Stock traded during the preceding ten (10) trading days and the applicable conversion price divided by $1,000,
subject to the Share Limit (below). At each conversion date, the conversion price for the Common Stock will equal the lower of
(i) 85% of the Common Stock's volume weighted average trading price (the "VWAP") during the 10-day trading period
immediately preceding the conversion date and (ii) 88% of the VWAP of the Common Stock on the trading day immediately prior to
the conversion date. The number of shares of Common Stock issued upon such conversion shall then be determined by multiplying the
number of shares of Series C Preferred Stock converted by $1,000 and dividing the product thereof by the conversion price for such
conversion date, subject to certain limitations.
In the event that the VWAP for the 20 trading
day period immediately prior to a conversion does not equal or exceed $0.20 (the "Floor"), as calculated with respect
to any subsequent conversion date, then such conversion will not occur and the shares not converted on that date will be added
to shares of Series C Preferred Stock to be converted on the following conversion date.
In addition, Seaside has the right to reduce
the number of shares of Series C Preferred Stock converted on any conversion date if the number of shares of Common Stock to be
received Seaside upon conversion is greater than twice the number of shares of Common Stock received by Seaside in connection with
the immediately preceding conversion (the "Share Limit"). In such event, Seaside may reduce the number of shares of
Series C Preferred Stock converted on such conversion date such that the number of shares of Common Stock to be received is an
amount equal to, as near as possible, the applicable Share Limit.
The Agreement contains representations
and warranties and covenants for each party, which must be true and have been performed at each closing. Additionally, the Company
has agreed to indemnify and hold harmless Seaside and its related parties against certain liabilities in connection with the issuance
and sale of the Series C Preferred Stock under the Agreement.
At the Initial Closing, Seaside converted
146.7916 shares of Series C Preferred Stock into 298,472 shares of Common Stock at the conversion price of $0.49181, and the Company
raised gross proceeds of $2,500,000 before estimated Offering expenses of approximately $200,000, which includes placement agent
and attorneys' fees.
The Offering is made pursuant to the Company's
shelf registration statement on Form S-3 (File No. 333-165221), which was declared effective by the Securities and Exchange Commission
on April 29, 2010. The Company, pursuant to Rule 424(b) under the Securities Act of 1933, has filed with the Securities and Exchange
Commission a prospectus supplement relating to the Offering.
In connection with the Offering, pursuant
to a Placement Agency Agreement dated March 3, 2010 by and between Midtown Partners & Co., LLC ("Midtown") and
the Company, as amended by an Underwriter Agent Agreement Amendment No. 1 dated March 28, 2011 (as amended, the "Placement
Agency Agreement"), the Company will pay Midtown a cash fee representing 6% of the gross purchase price paid by Seaside for
the Series C Preferred Stock.
The foregoing is only a summary of the
material terms of the Agreement and the Placement Agency Agreement. The foregoing description of the Agreement is qualified in
its entirety by reference to the Agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated
herein by reference. The foregoing description of the Placement Agency Agreement is qualified in its entirety by reference to the
Placement Agency Agreement and the Underwriter Agent Agreement Amendment No. 1, which are incorporated herein by reference.
This Current Report on Form 8-K contains
forward-looking statements that involve risk and uncertainties, such as statements related to the anticipated subsequent closings
of the Offering. The risks and uncertainties involved include the Company's ability to satisfy certain conditions to closing
on a timely basis or at all, the substantial dilution to current stockholders as a result of the purchase price discount offered
to Seaside, and the market overhang of shares available for sale that may develop as a result of the subsequent resale by Seaside
of the shares it may acquire under the Agreement, as well as other risks detailed from time to time in the Company's periodic
filings with the Securities and Exchange Commission.
Item 9.01
Financial Statements and Exhibits.
(d)
Exhibits.
Exhibit
Number
Description
1.1
Placement Agency Agreement, dated March 3, 2010, by and between NanoViricides, Inc. and Midtown Partners & Co., LLC.(1)
1.2
Underwriter Agent Agreement Amendment No. 1 dated March 28, 2011(2)
4.1
Certificate of Designation of Rights and Preferences of Series C Convertible Preferred Stock
10.1
Securities Purchase Agreement dated June 26, 2012 by and between NanoViricides, Inc. and Seaside 88, LP.
99.1
Press Release dated June 29, 2012
(1) Incorporated by reference from the Company's
Form 8-K filed on May 12, 2010.
(2) Incorporated by reference from the Company's
Form 8-K filed on April 19, 2011.
SIGNATURES
PURSUANT TO THE REQUIREMENTS OF THE SECURITIES EXCHANGE ACT
OF 1934, THE REGISTRANT HAS DULY CAUSED THIS REPORT TO BE SIGNED ON ITS BEHALF BY THE UNDERSIGNED THEREUNTO DULY AUTHORIZED.
NANOVIRICIDES, INC.
Date: June 29, 2012
By:
/s/ Anil Diwan
Anil Diwan, President
Exhibit Index
Exhibit
Number
Description
1.1
Placement Agency Agreement, dated March 3, 2010, by and between NanoViricides, Inc. and Midtown Partners & Co., LLC.(1)
1.2
Underwriter Agent Agreement Amendment No. 1 dated March 28, 2011(2)
4.1
Certificate of Designation of Rights and Preferences of Series C Convertible Preferred Stock
10.1
Securities Purchase Agreement dated June 26, 2012 by and between NanoViricides, Inc. and Seaside 88, LP.
99.1
Press Release dated June 29, 2012
(1) Incorporated by reference from the Company's
Form 8-K filed on May 12, 2010.
(2) Incorporated by reference from the Company's
Form 8-K filed on April 19, 2011.